Business Context and Reporting Period
Company: Marker Therapeutics, Inc. (MRKR)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2026
Business Overview: A clinical-stage immuno-oncology company developing Multi-Antigen Recognizing (MAR)-T cell therapies for hematological malignancies and solid tumors. The company has no commercial product revenue and relies on grants and capital raises to fund operations.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Grant Income | $751,691 | $349,104 |
| Total Operating Expenses | $4,072,535 | $4,957,777 |
| Net Loss | $(3,179,278) | $(4,446,184) |
| Net Loss Per Share (Basic/Diluted) | $(0.16) | $(0.40) |
| Cash, Cash Equivalents, & Restricted Cash | $15,638,655 | $13,693,208 |
| Working Capital | $13,795,958 | $14,491,871 |
| Net Cash Used in Operating Activities | $(1,404,192) | $(5,499,737) |
Material Changes vs. Prior Period
- Reduced Net Loss: Net loss decreased by 28% to $3.18 million, driven by a reduction in operating expenses and a 115% increase in grant income.
- Operating Expenses: Total operating expenses declined 18% to $4.07 million.
- Research & Development: Decreased 9% to $2.84 million, primarily due to lower stock-based compensation compared to the prior year.
- General & Administrative: Decreased 10% to $1.23 million due to reduced legal and professional fees.
- One-time Items: Q1 2025 included a $453,135 loss on the early termination of a vendor agreement with Cell Ready, LLC, which did not recur in Q1 2026.
- Grant Income: Increased significantly to $751,691, largely due to the recognition of income from the CPRIT Pancreatic Grant ($251,663) and the Decoy Grant ($98,634).
- Liquidity: Cash balances increased by approximately $1.9 million compared to the prior year period, though cash used in operations remained negative.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has raised substantial doubt regarding the company's ability to continue as a going concern. Based on current cash reserves and burn rate, the company expects to fund operations only into the first quarter of 2027 without additional funding.
- Capital Strategy: The company plans to raise additional capital through equity issuances and grant applications. An At-The-Market (ATM) offering agreement exists with H.C. Wainwright & Co., but there was no activity under this agreement during the quarter.
- Manufacturing Transition: The company terminated its agreement with Cell Ready, LLC in March 2025. In June 2025, it entered a new Statement of Work with Cellipont Bioservices to support cGMP manufacturing for the APOLLO study (MT-601).
- Clinical Progress: The Phase 1 APOLLO study for MT-601 in lymphoma patients showed objective responses and a favorable safety profile as of the June 2025 data cutoff.
- Related Party Transactions: Significant expenses ($1.11 million) were incurred related to Baylor College of Medicine (BCM) for research and manufacturing. A related party payable of $1.0 million was recorded as of March 31, 2026.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next capital raise given the "first quarter of 2027" liquidity horizon and the substantial doubt disclosure.
- Grant Sustainability: Confirm the status of uncollected grant receivables ($1.38 million) and the likelihood of receiving remaining funds from CPRIT, NIH, and FDA grants.
- Manufacturing Reliability: Assess the risks associated with the transition from BCM/Cell Ready to Cellipont Bioservices for clinical supply.
- Dilution Risk: Review the impact of outstanding warrants (7.67 million shares) and options (1.76 million shares) on future equity dilution.
- Related Party Dependence: Evaluate the financial impact of the $1.0 million payable to BCM and the reliance on BCM for core technology and manufacturing.